Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $55.13 | $5,513.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 69,762 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 200 | $53.97 | $10,794.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 69,862 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $53.80 to $54.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,118 | $53.12 | $59,388.16 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 70,062 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $52.77 to $53.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,800 | $55.14 | $99,252.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,543,342 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $54.88 to $55.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,700 | $54.24 | $146,448.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545,142 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $53.80 to $54.78. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 13,900 | $53.17 | $739,063.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,547,842 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $52.79 to $53.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,561,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,548 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $54.60 | $77,422.80 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 71,180 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $54.29 to $55.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 200 | $55.24 | $11,048.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,554,908 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $55.22 to $55.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,200 | $54.63 | $994,266.00 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,555,108 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $54.20 to $55.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 22:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-023885 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,573,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,382 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,418 | $55.83 | $79,166.94 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 72,598 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $55.32 to $55.98. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 8,758 | $55.85 | $489,134.30 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,566,474 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $55.65 to $56.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,642 | $55.37 | $533,877.54 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,575,232 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $54.65 to $55.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,216 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 990 | $55.83 | $55,271.70 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 74,016 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $55.59 to $56.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 428 | $55.09 | $23,578.52 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 75,006 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $54.89 to $55.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,266 | $55.83 | $405,660.78 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,578,040 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $55.495 to $56.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,134 | $55.14 | $613,928.76 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,585,306 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $54.48 to $55.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-021059 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,596,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · derivative · entry 15 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,050 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $55.45 | $5,545.00 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 75,434 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,318 | $54.89 | $72,345.02 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 75,534 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $54.42 to $55.22. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,200 | $55.47 | $66,564.00 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,589,606 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $55.32 to $55.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 17,200 | $54.90 | $944,280.00 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,590,806 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $54.31 to $55.29. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,608,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 00:08 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 15,049 | $55.58 | $836,423.42 |
DisclosureSEC source: 0001209191-19-017534 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612,738 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,834 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,884 Underlying: Common Stock · 6,834 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 600 | $56.86 | $34,116.00 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 76,852 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $56.70 to $57.11. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 818 | $55.81 | $45,652.58 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 77,452 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $55.50 to $56.22. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,100 | $57.68 | $63,448.00 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,601,172 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $57.50 to $57.88. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,836 | $56.84 | $445,398.24 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,602,272 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $56.50 to $57.49. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,464 | $55.84 | $528,469.76 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,610,108 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $55.50 to $56.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 23:41 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,834 | $2.90 | $19,818.60 |
DisclosureSEC source: 0001209191-19-018277 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,619,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 00:08 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,288 | $58.69 | $134,282.72 |
DisclosureSEC source: 0001209191-19-017534 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,627,787 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $57.41 | $23,997.38 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 78,270 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $57.35 to $57.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 500 | $56.76 | $28,380.00 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 78,688 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $56.29 to $57.21. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,850 | $57.47 | $566,079.50 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,630,575 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $57.22 to $57.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,050 | $56.71 | $513,225.50 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,640,425 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $56.22 to $57.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,649,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,319 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $57.67 | $52,941.06 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 79,188 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $57.34 to $57.88. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 800 | $58.26 | $46,608.00 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639,156 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $58.07 to $58.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,100 | $57.69 | $1,044,189.00 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639,956 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $57.34 to $57.98. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:47 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-19-012324 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,658,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · derivative · entry 15 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,638 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.